基于网络药理学探讨血必净注射液治疗新型冠状病毒肺炎机制的中药研究

Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019.

作者信息

Xing Yan, Hua Ying-Rong, Shang Jing, Ge Wei-Hong, Liao Jun

机构信息

School of Science, China Pharmaceutical University, Nanjing 211198, China.

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

出版信息

Chin J Nat Med. 2020 Dec;18(12):941-951. doi: 10.1016/S1875-5364(20)60038-3.

Abstract

As a representative drug for the treatment of severe community-acquired pneumonia and sepsis, Xuebijing (XBJ) injection is also one of the recommended drugs for the prevention and treatment of coronavirus disease 2019 (COVID-19), but its treatment mechanism for COVID-19 is still unclear. Therefore, this study aims to explore the potential mechanism of XBJ injection in the treatment of COVID-19 employing network pharmacology and molecular docking methods. The corresponding target genes of 45 main active ingredients in XBJ injection and COVID-19 were obtained by using multiple database retrieval and literature mining. 102 overlapping targets of them were screened as the core targets for analysis. Then built the PPI network, TCM-compound-target-disease, and disease-target-pathway networks with the help of Cytoscape 3.6.1 software. After that, utilized DAVID to perform gene ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis to predict the action mechanism of overlapping targets. Finally, by applying molecular docking technology, all compounds were docked with COVID-19 3 CL protease(3CLpro), spike protein (S protein), and angiotensin-converting enzyme II (ACE2). The results indicated that quercetin, luteolin, apigenin and other compounds in XBJ injection could affect TNF, MAPK1, IL6 and other overlapping targets. Meanwhile, anhydrosafflor yellow B (AHSYB), salvianolic acid B (SAB), and rutin could combine with COVID-19 crucial proteins, and then played the role of anti-inflammatory, antiviral and immune response to treat COVID-19. This study revealed the multiple active components, multiple targets, and multiple pathways of XBJ injection in the treatment of COVID-19, which provided a new perspective for the study of the mechanism of traditional Chinese medicine (TCM) in the treatment of COVID-19.

摘要

血必净(XBJ)注射液作为治疗重症社区获得性肺炎和脓毒症的代表性药物,也是预防和治疗新型冠状病毒肺炎(COVID-19)的推荐药物之一,但其治疗COVID-19的机制仍不清楚。因此,本研究旨在采用网络药理学和分子对接方法探索血必净注射液治疗COVID-19的潜在机制。通过多个数据库检索和文献挖掘,获得了血必净注射液中45种主要活性成分和COVID-19的相应靶基因。筛选出其中102个重叠靶标作为核心靶标进行分析。然后借助Cytoscape 3.6.1软件构建蛋白质-蛋白质相互作用(PPI)网络、中药-化合物-靶标-疾病网络和疾病-靶标-通路网络。之后,利用DAVID进行基因本体(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析,以预测重叠靶标的作用机制。最后,应用分子对接技术,将所有化合物与COVID-19 3C样蛋白酶(3CLpro)、刺突蛋白(S蛋白)和血管紧张素转换酶II(ACE2)进行对接。结果表明,血必净注射液中的槲皮素、木犀草素、芹菜素等化合物可影响肿瘤坏死因子(TNF)、丝裂原活化蛋白激酶1(MAPK1)、白细胞介素6(IL6)等重叠靶标。同时,脱水红花黄色素B(AHSYB)、丹酚酸B(SAB)和芦丁可与COVID-19关键蛋白结合,进而发挥抗炎、抗病毒和免疫反应作用来治疗COVID-19。本研究揭示了血必净注射液治疗COVID-19的多个活性成分、多个靶标和多条通路,为中医药治疗COVID-19的机制研究提供了新的视角。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索